- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. Financial Highlights:
Consolidated revenue grew 28% YoY to Rs. 705 Cr in Q4, with FY25 revenue up 44% at Rs. 2,894 Cr. EBITDA surged 70% YoY in Q4 to Rs. 252 Cr, reaching Rs. 1,017 Cr for the full year (+51%). EBITDA margins expanded to 36% in Q4 and 35.2% for FY25. PAT increased 28% YoY in Q4 to Rs. 102 Cr, with EPS also up 28%. Gross margin declined 269 bps YoY due to product mix shifts but was offset by a 1,153 bps reduction in fixed expenses as a percentage of revenue. Operating cash flow remained strong, with OCF-to-EBITDA at 111% in Q4 and 105% for FY25. ROCE improved from 11% to 15%, adjusted ROCE at 20%. Net debt fell significantly to Rs. 2,222 Cr (2.2x Debt/EBITDA), aiming for 1.5x by FY26.
2. Strategic Initiatives & Growth Drivers:
Eris is deepening its diabesity focus through a strong pipeline of insulin analogs, GLP-1 agonists, and combo therapies, with launches planned through FY27-28. Insulin insourcing at Bhopal is accelerating to improve margins and supply control. Capex includes Rs. 100-120 Cr for a new injectable block at Eris-AMD and Rs. 50 Cr for GLP-1 validation expansion. New divisions (RISE, STRIDES) adding ~260 reps drive growth in vitamins, minerals, nutraceuticals, and IVF therapies. Organic DBF revenue growth is guided at 15-21% for FY26; gross DBF revenue expected at Rs. 2,900–3,050 Cr.
3. Business Developments:
One year post-acquisition, Biocon-2 insulin reported Rs. 386 Cr revenue with 22% growth despite shortages. Fill-finish operations at Bhopal began, with cartridge supply expected Q3 FY26 to boost margins. Swiss Parenterals grew 12% to Rs. 326 Cr revenue; EBITDA jumped 40% to Rs. 109 Cr. Rs. 100-120 Cr capex planned for injectable expansion, aiming for commercial scale CDMO and injectable launches by Q4 FY26. Oral solid dose exports to ROW and Latam markets are rising.
4. Market Position & Competitive Advantage:
Eris is India's 2nd largest insulin player with a 10% market share, targeting #3 in anti-diabetes by FY28. It boasts a differentiated pipeline of first-in-market oral solid combos and a unique patient care model for diabesity and obesity management. A strong partnership with Biocon secures insulin supply. In-house production is scaling towards ~80% by Q4 FY26, enhancing margins and supply security. Upcoming generic obesity treatments like gSaxenda complement its insulin portfolio, underpinning a strong competitive edge.
5. Investor Implications:
Robust revenue and margin growth, notable debt reduction, and solid operating cash flow signal positive growth potential. Key drivers include insulin insourcing, new product launches, and diabesity market penetration. Margin gains from expanded in-house manufacturing and Swiss Parenterals’ scaling add further upside. Investors should watch execution risks related to approvals and capacity ramp-up but can expect accelerating EPS growth and improving returns through FY26-28.